Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee
M Mino-Kenudson, K Schalper, W Cooper… - Journal of Thoracic …, 2022 - Elsevier
Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227
JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
MM Awad, R Govindan, KN Balogh, DR Spigel… - Cancer Cell, 2022 - cell.com
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
V Mollica, A Rizzo, A Marchetti, V Tateo… - Clinical and …, 2023 - Springer
ECOG performance status (PS) is a pivotal prognostic factor in a wide number of solid
tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in …
tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in …
[HTML][HTML] First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate …
S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir… - Annals of oncology, 2022 - Elsevier
Background In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …
Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of …
RI Haddad, K Harrington, M Tahara… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade
Over 500 clinical trials are investigating combination radiotherapy and immune checkpoint
blockade (ICB) as cancer treatments; however, the majority of trials have found no positive …
blockade (ICB) as cancer treatments; however, the majority of trials have found no positive …